Pheon Therapeutics Ltd

POWER SEARCH PRICING

SOLUTIONS

pheon therapeutics ltd Company Information

Live

YoungSmallHigh

Company Number

09677410

Website

www.femtogenix.com

Registered Address

innovation house innovation way, discovery park, sandwich, kent, CT13 9FF

Industry

Research and experimental development on biotechnology

Telephone

02038580153

Next Accounts Due

December 2024

Group Structure

View All

Directors

Shaun Kirkpatrick9 Years

Jonathan Tobin2 Years

View All

Shareholders

research corporation technologies inc 28.1%

atlas venture fund xii l p 19.4%

View All

pheon therapeutics ltd Estimated Valuation

£31.5m

Pomanda estimates the enterprise value of PHEON THERAPEUTICS LTD at £31.5m based on Net Assets of £14.1m and 2.24x industry multiple (adjusted for liquidity).

Edit your figures and get a professional valuation report.

Pheon Therapeutics Ltd is a live company located in sandwich, CT13 9FF with a Companies House number of 09677410. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in July 2015, it's largest shareholder is research corporation technologies inc with a 28.1% stake. Pheon Therapeutics Ltd is a young, small sized company, Pomanda has estimated its turnover at £818.5k with high growth in recent years.

View Sample

Upgrade for unlimited company reports & a free credit check

Pomanda's financial health check has awarded Pheon Therapeutics Ltd a 5 rating. We use a traffic light system to show it exceeds the industry average on 6 measures and has 3 areas for improvement. Company Health Check FAQs

Health Rating5out of 5

6 Strong

2 Regular

3 Weak

Size

annual sales of £818.5k, make it smaller than the average company (£3m)

Growth

3 year (CAGR) sales growth of 22%, show it is growing at a faster rate (13.1%)

EXPORT

Pheon Therapeutics Ltd's latest turnover from March 2023 is estimated at £818.5 thousand and the company has net assets of £14.1 million. According to their latest financial statements, Pheon Therapeutics Ltd has 4 employees and maintains cash reserves of £13.4 million as reported in the balance sheet.

Data source: Companies House, Pomanda Estimates

	Mar 2023	Mar 2022	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016
Turnover	818,524	607,933	451,232	625,958	740,291	858,386	568,727
Other Income Or Grants	0	0	0	0	0	0	0
Cost Of Sales	377,945	308,815	215,602	308,796	356,750	424,149	296,330
Gross Profit	440,579	299,119	235,630	317,162	383,542	434,237	272,398
Admin Expenses	10,847,357	8,856,069	1,561,390	1,859,539	1,751,096	1,268,687	1,106,790
Operating Profit	-10,406,778	-8,556,950	-1,325,760	-1,542,377	-1,367,554	-834,450	-834,392
Interest Payable	0	0	0	0	0	0	0
Interest Receivable	783,954	88,133	546	4,472	1,869	3,518	1,537
Pre-Tax Profit	-9,622,824	-8,468,817	-1,325,214	-1,537,905	-1,365,685	-830,932	-832,855
Tax	0	0	0	0	0	0	0
Profit After Tax	-9,622,824	-8,468,817	-1,325,214	-1,537,905	-1,365,685	-830,932	-832,855
Dividends Paid	0	0	0	0	0	0	0
Retained Profit	-9,622,824	-8,468,817	-1,325,214	-1,537,905	-1,365,685	-830,932	-832,855
Employee Costs	284,726	433,691	563,591	614,203	607,886	611,576	461,573
Number Of Employees	4	6	8	9	9	10	8
EBITDA*	-10,376,207	-8,477,141	-1,251,748	-1,469,779	-1,303,549	-803,862	-827,441

* Earnings Before Interest, Tax, Depreciation and Amortisation

	Mar 2023	Mar 2022	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016
Tangible Assets	20,044	45,214	120,739	197,287	236,290	239,579	114,819
Intangible Assets	0	0	1	79	157	235	313
Investments & Other	0	0	0	0	0	0	0
Debtors (Due After 1 year)	0	0	0	0	0	0	0
Total Fixed Assets	20,044	45,214	120,740	197,366	236,447	239,814	115,132
Stock & work in progress	0	0	0	0	0	0	0
Trade Debtors	35,000	40,000	5,000	3,840	0	0	0
Group Debtors	44,733	0	0	0	0	0	0
Misc Debtors	2,406,448	110,708	146,401	144,536	377,672	355,169	190,380
Cash	13,389,911	23,502,060	221,049	871,647	321,002	177,398	1,229,762
misc current assets	0	0	0	0	0	0	0
total current assets	15,876,092	23,652,768	372,450	1,020,023	698,674	532,567	1,420,142
total assets	15,896,136	23,697,982	493,190	1,217,389	935,121	772,381	1,535,274
Bank overdraft	0	0	0	0	0	0	0
Bank loan	0	0	0	0	0	0	0
Trade Creditors	924,318	252,049	51,430	238,584	49,282	80,978	23,773
Group/Directors Accounts	0	0	0	0	0	0	0
other short term finances	0	0	0	0	0	0	0
hp & lease commitments	0	0	0	0	0	0	0
other current liabilities	908,794	116,382	75,451	71,413	74,940	28,352	21,173
total current liabilities	1,833,112	368,431	126,881	309,997	124,222	109,330	44,946
loans	0	0	0	0	0	0	0
hp & lease commitments	0	0	0	0	0	0	0
Accruals and Deferred Income	0	0	0	0	0	0	0
other liabilities	0	0	2,458,718	1,641,041	0	0	0
provisions	0	0	0	33,552	40,196	26,674	23,026
total long term liabilities	0	0	2,458,718	1,674,593	40,196	26,674	23,026
total liabilities	1,833,112	368,431	2,585,599	1,984,590	164,418	136,004	67,972
net assets	14,063,024	23,329,551	-2,092,409	-767,201	770,703	636,377	1,467,302
total shareholders funds	14,063,024	23,329,551	-2,092,409	-767,201	770,703	636,377	1,467,302

	Mar 2023	Mar 2022	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016
Operating Activities
Operating Profit	-10,406,778	-8,556,950	-1,325,760	-1,542,377	-1,367,554	-834,450	-834,392
Depreciation	30,571	79,808	73,934	72,520	63,927	30,510	6,873
Amortisation	0	1	78	78	78	78	78
Tax	0	0	0	0	0	0	0
Stock	0	0	0	0	0	0	0
Debtors	2,335,473	150,708	3,025	-229,296	22,503	164,789	190,380
Creditors	672,269	252,049	-187,154	189,302	-31,696	57,205	23,773
Accruals and Deferred Income	792,412	116,382	4,038	-3,527	46,588	7,179	21,173
Deferred Taxes & Provisions	0	0	-33,552	-6,644	13,522	3,648	23,026
Cash flow from operations	-11,246,999	-8,259,418	-1,471,441	-1,061,352	-1,297,638	-900,619	-949,849
Investing Activities
capital expenditure	-5,401	-125,023	2,614	-33,517	-60,638	-155,270	-122,083
Change in Investments	0	0	0	0	0	0	0
cash flow from investments	-5,401	-125,023	2,614	-33,517	-60,638	-155,270	-122,083
Financing Activities
Bank loans	0	0	0	0	0	0	0
Group/Directors Accounts	0	0	0	0	0	0	0
Other Short Term Loans	0	0	0	0	0	0	0
Long term loans	0	0	0	0	0	0	0
Hire Purchase and Lease Commitments	0	0	0	0	0	0	0
other long term liabilities	0	0	817,677	1,641,041	0	0	0
share issue	356,297	31,798,368	6	1	1,500,011	7	2,300,157
interest	783,954	88,133	546	4,472	1,869	3,518	1,537
cash flow from financing	1,140,251	31,886,501	818,229	1,645,514	1,501,880	3,525	2,301,694
cash and cash equivalents
cash	-10,112,149	23,502,060	-650,598	550,645	143,604	-1,052,364	1,229,762
overdraft	0	0	0	0	0	0	0
change in cash	-10,112,149	23,502,060	-650,598	550,645	143,604	-1,052,364	1,229,762

Very Low Risk70 - 100

Low Risk50 - 70

Moderate Risk30 - 50

High Risk20 - 30

Very High Risk0 - 20

Get a comprehensive credit check for pheon therapeutics ltd. Get real-time insights into pheon therapeutics ltd's credit score, group structure and payment trends.

From as little as £6.99

This will not impact your credit rating!

View Credit Report Sample

Perform a competitor analysis for pheon therapeutics ltd by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other small companies, companies in CT13 area or any other competitors across 12 key performance metrics.

PHEON THERAPEUTICS LTD group structure

Pheon Therapeutics Ltd has no subsidiary companies.

Ultimate parent company

PHEON THERAPEUTICS LTD

09677410

PHEON THERAPEUTICS LTD Shareholders

research corporation technologies inc	28.12%
atlas venture fund xii l p	19.4%
forbion capital fund v cooperatief u.a.	19.4%
mr cyrus mozayeni	8.17%
hostplus pty ltd	7.1%
mrcf5 service (h) pty ltd	3.55%
mrcf5 service (ts) pty ltd	2.58%
kings college london	2.57%
mr bertrand damour	1.89%
mrcf5 service (sw) pty ltd	1.61%

Pheon Therapeutics Ltd currently has 7 directors. The longest serving directors include Mr Shaun Kirkpatrick (Sep 2015) and Mr Jonathan Tobin (Mar 2022).

officer	country	age	start	end	role
Mr Shaun Kirkpatrick	United States	55 years	Sep 2015	-	Director
Mr Jonathan Tobin	United Kingdom	41 years	Mar 2022	-	Director
President Michael Gladstone	United States	38 years	Mar 2022	-	Director
Dr Rogier Rooswinkel	Netherlands	41 years	Mar 2022	-	Director
Dr Rogier Rooswinkel	Netherlands	41 years	Mar 2022	-	Director
Mr Jeffery Albers	United Kingdom	53 years	Jan 2023	-	Director
Mr Cyrus Mozayeni	United Kingdom	50 years	Jul 2023	-	Director

P&L

March 2023

turnover

818.5k

+35%

operating profit

-10.4m

gross margin

53.9%

+9.4%

turnover

Turnover, or revenue, is the amount of sales generated by a company within the financial year.

Balance Sheet

March 2023

net assets

14.1m

-0.4%

total assets

15.9m

-0.33%

cash

13.4m

-0.43%

net assets

Total assets minus all liabilities

Similar Companies

st&i partnerships limited

anaero technology limited

2.5

superx limited

kaerus bioscience limited

european source ltd

company number

09677410

Type

Private limited with Share Capital

industry

72110 - Research and experimental development on biotechnology

incorporation date

July 2015

accounts

Total Exemption Full

ultimate parent company

None

previous names

femtogenix ltd (August 2022)

last accounts submitted

March 2023

address

innovation house innovation way, discovery park, sandwich, kent, CT13 9FF

A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.

We did not find charges/mortgages relating to pheon therapeutics ltd.

pheon therapeutics ltd Company Information

pheon therapeutics ltd Estimated Valuation

pheon therapeutics ltd Estimated Valuation

pheon therapeutics ltd Estimated Valuation

Pheon Therapeutics Ltd Overview

Pheon Therapeutics Ltd Health Check

PHEON THERAPEUTICS LTD financials

pheon therapeutics ltd Credit Report and Business Information

Pheon Therapeutics Ltd Competitor Analysis

pheon therapeutics ltd Ownership

pheon therapeutics ltd directors

pheon therapeutics ltd company details

pheon therapeutics ltd Charges & Mortgages

pheon therapeutics ltd Companies House Filings - See Documents